Cargando…

Longitudinal proteomics study of serum changes after allogeneic HSCT reveals potential markers of metabolic complications related to aGvHD

Even though hematopoietic stem cell transplantation (HSCT) allows successful treatment for many malignant and non-malignant disorders, its curative potential remains limited by severe side effects, including infections and other transplant-related complications such as graft-versus-host disease (GvH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Sing Ying, Kato, Seiko, Rodenburg, Frans, Tojo, Arinobu, Hayashi, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385631/ https://www.ncbi.nlm.nih.gov/pubmed/35977993 http://dx.doi.org/10.1038/s41598-022-18221-9

Ejemplares similares

Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation
por: Lv, Meng, et al.
Publicado: (2013)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders
por: Biagi, Elena, et al.
Publicado: (2019)

An Intelligent Clinical Decision Support System for Predicting Acute Graft-versus-host Disease (aGvHD) following Allogeneic Hematopoietic Stem Cell Transplantation
por: Salehnasab, Cirruse, et al.
Publicado: (2021)

Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients
por: Pan, Zengkai, et al.
Publicado: (2022)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Antibody- and aptamer-strategies for GvHD prevention
por: Oelkrug, Christopher, et al.
Publicado: (2015)

Established and Emerging Treatments of Skin GvHD
por: Link-Rachner, Cornelia S., et al.
Publicado: (2022)

Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
por: Buxbaum, Nataliya P., et al.
Publicado: (2022)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

The Role of Bacteria and Pattern Recognition Receptors in GvHD
por: Holler, E., et al.
Publicado: (2010)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
por: Mohammadpour, Hemn, et al.
Publicado: (2023)

New insights about immune populations in gastrointestinal GvHD
por: Hayase, Eiko, et al.
Publicado: (2023)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
por: Wang, Lan, et al.
Publicado: (2022)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

Effects of immune system cells in GvHD and corresponding therapeutic strategies
por: Tavaf, Maryam Jadid, et al.
Publicado: (2023)

CrkL is required for donor T cell migration to GvHD target organs
por: Roy, Nathan H., et al.
Publicado: (2020)

Accumulation of T-cell-suppressive PD-L1(high) extracellular vesicles is associated with GvHD and might impact GvL efficacy
por: Baur, Rebecca, et al.
Publicado: (2023)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

The Potential Genes Mediate the Pathogenicity of Allogeneic CD4(+)T Cell in aGVHD Mouse Model
por: Yu, Zhengyu, et al.
Publicado: (2021)

Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum
por: Hayashi, Nobuhiro, et al.
Publicado: (2019)

Antigen-Specific Priming is Dispensable in Depletion of Apoptosis-Sensitive T Cells for GvHD Prophylaxis
por: Yarkoni, Shai, et al.
Publicado: (2014)

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells
por: Riegel, Christin, et al.
Publicado: (2019)

Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
por: Roberto, Crocchiolo, et al.
Publicado: (2021)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
por: Bojanic, Ines, et al.
Publicado: (2023)

Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
por: Héritier, Jérémie, et al.
Publicado: (2022)

Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
por: Crocchiolo, Roberto, et al.
Publicado: (2021)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2022)

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
por: Li, Yan-Ruide, et al.
Publicado: (2022)

Pneumothorax in an Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation
por: Ebihara, Yasuhiro, et al.
Publicado: (2013)

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
por: Morris, Emma C., et al.
Publicado: (2019)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g8dk5mqbt2d26dqaf7eeumvn5v